Cytokinetics, Incorporated
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cytokinetics, Incorporated's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-43.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 70% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 7%
Sales fell 7% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-7% / +40%In 3 years sales changed by -7% while total assets changed by +40%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-12.4×Operating cash was negative last year, while some debt falls due within a year.
Higher than 53% of Healthcare companies in United States.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 73% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Cytokinetics, Incorporated made a loss over the last year. Cytokinetics, Incorporated owes $1.09 for every $1 it owns. Cytokinetics, Incorporated made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCytokinetics, Incorporated made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-49.95Cytokinetics, Incorporated's book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$8.7 BThe total market value of all of Cytokinetics, Incorporated's shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeCytokinetics, Incorporated's net worth is negative ($173 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.09×Cytokinetics, Incorporated owes $1.09 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Dividend yield
NoneCytokinetics, Incorporated does not currently pay a dividend.
Revenue growth
+377%Revenue rose 377% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Profit growth
LossCytokinetics, Incorporated made a loss in each of the last two years.
Profit margin
-891.6%Cytokinetics, Incorporated lost $892 for every $100 of revenue.
Interest cover
Not coveredCytokinetics, Incorporated's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtCytokinetics, Incorporated had $402 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Cytokinetics, Incorporated owe compared with what it owns?
Cytokinetics, Incorporated owes $1.09 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Does Cytokinetics, Incorporated pay a dividend?
No. Cytokinetics, Incorporated does not currently pay a dividend.
Is Cytokinetics, Incorporated's revenue growing?
Revenue rose 377% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.